NASDAQ: RDNT · Diagnostics & Research
RadNet (RDNT) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values RadNet (RDNT) at $72.24 a share. The stock last closed at $76.89, which puts the model's fair value 6.0% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. RadNet, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $78.41 to $72.24 (-7.9%). The peer group changed: most of the move.
What the model makes of itThe price of $76.89 is 6.0% above it: Fairly valued, on a medium evidence grade.
What's nextNext report on 1 Mar 2027. Options prices imply a move of about 13% either way over the next month. On the model's Earnings Momentum list since 30 Oct 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give RDNT?
The calibrated range for RDNT over 63 trading days is $66.45 to $89.62. It sits around the last close, and its width comes from the volatility that RDNT's own options imply (44% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $55.09 to $93.00. In 43% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
RadNet, Inc. operates as a prominent healthcare services company specialising in outpatient diagnostic imaging across the United States. Its ticker is RDNT, and it sits in the Healthcare, Diagnostics & Research group.
Faircurve's model gave RadNet a fair value of $72.24 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $78.41, a move of -7.9%. In the model's own words, the peer group changed, which was most of the move. The calibrated range over 63 trading days is $66.45 to $89.62. Across 8,038 past valuations, ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium, based on input completeness, comparable companies and the width of outcomes. It does not say whether the fair value is right.
RadNet scores 53 out of 100 on the model's overall quality score, a composite of six quality factors measured against comparable companies. Earnings quality scores 100. Growth quality scores 81, with trailing revenue growth of 11.5% against a peer median of 6.3%. Profitability scores 18, with ROIC of 2.0% against a peer median of 8.5%. The model compares RadNet with Sotera Health Company, Charles River Laboratories International, Revvity, NeoGenomics, Medpace Holdings and Quest Diagnostics.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does RDNT report earnings, and how has the stock reacted?
RadNet's next earnings report is scheduled for 1 Mar 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 10.3% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. RDNT's 30 day implied volatility works out to about 12.8% over one month.
Around its last 2 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across RDNT's last 8 reports, ignoring direction, was 3.9%.
Earlier reports are left out: the options record before 23 Sep 2026 is not comparable.
How does RDNT score on business quality?
RadNet's overall quality score is 53 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 18 | 2.0%ROIC | 8.5% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 81 | 11.5%Revenue growth, trailing | 6.3% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 24 | 0.0%Net buybacks / market value | 0.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 28 | 4.82xNet debt / EBITDA | 3.61x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 58 | 2.4 ptsEBITDA margin downside volatility, 5y | 1.8 pts |
How does RDNT compare with similar companies?
The companies in diagnostics & research closest to RadNet in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| SHC Sotera Health Company | $16.25 | $22.46 | +38.2% | Undervalued |
| CRL Charles River Laboratories International, Inc. | $335.52 | $423.73 | +26.3% | Undervalued |
| RVTY Revvity, Inc. | $148.85 | $185.05 | +24.3% | Undervalued |
| NEO NeoGenomics, Inc. | $15.41 | $15.88 | +3.0% | Fairly valued |
| MEDP Medpace Holdings, Inc. | $648.20 | $717.73 | +10.7% | Fairly valued |
| VCYT Veracyte, Inc. | $24.01 | $27.86 | +16.0% | Data under review |
| DGX Quest Diagnostics Incorporated | $262.21 | $314.32 | +19.9% | Undervalued |
| LH Labcorp Holdings Inc. | $372.46 | $465.68 | +25.0% | Low evidence grade |
What the comparable companies' multiples alone would give for RDNT, the peer-implied price, is $47.64 a share on this run. The fair value weighs that against the company's own multiple.
All diagnostics & research stocks ranked by gap to fair value
RadNet at a glance
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States.
- Market value
- $6.0B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Revenue expected, next twelve months
- $2.8B
- Consensus revenue growth, next fiscal year
- +23.2%
- Analysts with estimates
- 3
- Beta to the US market
- 1.02
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. RDNT was not among them.
How the fair value is worked out: the model prices RadNet on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for RDNT was $78.41. As of 14 Nov 2026 it is $72.24, a change of -7.9%. The peer group changed: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about RadNet's valuation
Is RadNet stock undervalued or overvalued?
On Faircurve's model, RDNT reads as Fairly valued as of 14 Nov 2026. The model's fair value is $72.24 a share against a last close of $76.89, a gap of -6.0%.
What is RDNT's fair value?
$72.24 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $55.09 to $93.00.
What price range does the model give RDNT?
$66.45 to $89.62 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does RadNet report earnings next?
The next report is scheduled for 1 Mar 2027. Companies can move their dates.
How much has RDNT moved on past earnings reports?
Across its last 8 reports the median two session move was 3.9%, ignoring direction. The largest was +19.2% around the report of 11 Aug 2025.
How confident is the model in this valuation?
The model's evidence grade for RDNT is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on RDNT
The model has an idea open on RDNT under Earnings Momentum since 30 Oct 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on RDNT with their outcomes. A free account is enough.